Under Chin Fat Removal.
Belkyra® NZ is an individually-tailored, injectable treatment that permanently destroys fat cells under the chin. There is a common misconception that fullness under the chin only appears in those who are overweight, when in reality it can occur in any body type and may be related to ageing, genetics or weight gain.
Dr Mark Morunga talks about Belkyra®
What is Belkyra?
|
Belkyra® NZ is an individually-tailored, injectable treatment that permanently destroys fat cells under the chin. There is a common misconception that fullness under the chin only appears in those who are overweight, when in reality it can occur in any body type and may be related to ageing, genetics or weight gain.
More than 67 per cent of people are bothered by the fat or fullness under their chin, similar to the percentage of patients who are bothered by lines and wrinkles. Belkyra® is a prescription medicine for the treatment of moderate-to-severe convexity or fullness associated with sub-mental fat (often called double chin) in adults when the presence of sub-mental fat has a psychological impact for the patient. Fullness under the chin can impact how a person feels about themselves and, for both women and men, can lead to feelings of negative self-impression. |
|
Double Chin Removal in Auckland
Belkyra® one of the first clinically evaluated and approved treatments that is a non-surgical injectable treatment for reduction of fullness under the chin that has undergone rigorous clinical evaluation, including clinical studies involving more than 2,600 patients worldwide.
Until now, treatment options for sub-mental fullness have been limited to surgical options such as liposuction and non-surgical in-clinic procedures using handheld devices or aggressive weight-loss regimens with potentially limited improvement. When injected into fat under the chin, BELKYRA® permanently causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
Until now, treatment options for sub-mental fullness have been limited to surgical options such as liposuction and non-surgical in-clinic procedures using handheld devices or aggressive weight-loss regimens with potentially limited improvement. When injected into fat under the chin, BELKYRA® permanently causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
Treatment
Treatment with Belkyra® takes place in-clinic by Dr Mark Morunga. Many people experience improvement after 2-4 treatment sessions spaced at least 4 weeks apart. Dr Morunga will carry out a full facial assessment to help determine how many treatment sessions may be needed, based on the amount and distribution of the fat under the chin and patients personal treatment goals.
Clinical studies have evaluated the efficacy and safety of Belkyra® in adults with moderate-to-severe fullness under the chin. In these studies, Belkyra® was shown to have a high overall efficacy rate, demonstrated by an improvement in the reduction in fullness under the chin as assessed by the clinician in the study at 12 weeks after the last treatment. In the clinical studies, Belkyra® was generally well tolerated. Most side effects (including injection site pain/swelling and bruising) were mild or moderate in severity, primarily associated with the treatment area and resolved without intervention.
Clinical studies have evaluated the efficacy and safety of Belkyra® in adults with moderate-to-severe fullness under the chin. In these studies, Belkyra® was shown to have a high overall efficacy rate, demonstrated by an improvement in the reduction in fullness under the chin as assessed by the clinician in the study at 12 weeks after the last treatment. In the clinical studies, Belkyra® was generally well tolerated. Most side effects (including injection site pain/swelling and bruising) were mild or moderate in severity, primarily associated with the treatment area and resolved without intervention.
Before & After
|
|
Important Things To Check
- The qualifications and experience of the consulting doctor
- The level of customisation involved in any treatment and the expected outcome (double chin treatment should be tailored to your anatomy and circumstances)
- The quality of the facility where the procedures will be performed
- Any side effects and expected downtime
- The level of ‘after care’ that is offered by the clinic
- How comfortable you feel with the consulting doctor and other staff
- The total cost and duration of the proposed double chin treatment.
Patient Information
Belkyra® is a prescription medicine, which non surgically reduces fat under the chin, resulting in a more contoured neck profile and jawline.
Belkyra® has risks and benefits. for further information talk to your healthcare professional or check the Consumer Medicine Information at www.medsafe.govt.nz
Warnings: Do not use in the presence of infection. Should be administered by the subcutaneous route. Marginal mandibular nerve injury, difficulty in swallowing. Avoid injection into salivary glands, thyroid gland, lymph nodes and muscles. Screen for other pre-existing conditions and treatments.
Possible adverse reactions: Headache, nausea, difficulty swallowing, skin tightness, injection site bruising, discolouration. Injection site nerve injury, high blood pressure.
Deoxycholic acid 10mg/ml solution for injection.
Allergan New Zealand Ltd.
Belkyra® has risks and benefits. for further information talk to your healthcare professional or check the Consumer Medicine Information at www.medsafe.govt.nz
Warnings: Do not use in the presence of infection. Should be administered by the subcutaneous route. Marginal mandibular nerve injury, difficulty in swallowing. Avoid injection into salivary glands, thyroid gland, lymph nodes and muscles. Screen for other pre-existing conditions and treatments.
Possible adverse reactions: Headache, nausea, difficulty swallowing, skin tightness, injection site bruising, discolouration. Injection site nerve injury, high blood pressure.
Deoxycholic acid 10mg/ml solution for injection.
Allergan New Zealand Ltd.
We have the latest equipment, maintain the highest standards, and make your comfort and privacy our highest priority. Our clients receive the best possible outcomes in the safest and most beautiful of environments.
References
- Raspaldo H, et al. (2015). "Double-blind, placebo-controlled study evaluating the safety and efficacy of deoxycholic acid for the treatment of submental fat." Aesthetic Surgery Journal, 35(3), 327-333.
- Cohen JL, et al. (2015). "Safety and efficacy of deoxycholic acid injection for moderate-to-severe submental fat: A randomized, controlled trial." JAMA Dermatology, 151(12), 1282-1289.
- Mroz A, et al. (2016). "Deoxycholic acid for the treatment of submental fat: A review of clinical studies and real-world outcomes." Dermatologic Surgery, 42(5), 667-673.
- Swift A, et al. (2015). "Efficacy and safety of deoxycholic acid injection for moderate-to-severe submental fat." JAMA Facial Plastic Surgery, 17(3), 216-223.
- Jalian HR, et al. (2016). "A systematic review of deoxycholic acid for the treatment of submental fullness." Aesthetic Plastic Surgery, 40(5), 697-703.
- Liu C, et al. (2017). "Long-term safety and effectiveness of deoxycholic acid for submental fat reduction." Aesthetic Surgery Journal, 37(4), 420-426.
- Dayan SH, et al. (2016). "Aesthetic outcomes of submental fat treatment with deoxycholic acid injections: Results from a multi-center, randomized, double-blind trial." Journal of Drugs in Dermatology, 15(12), 1471-1476.
- Miller M, et al. (2017). "Comparing the safety and efficacy of deoxycholic acid to liposuction in the treatment of submental fat." Dermatologic Surgery, 43(9), 1110-1117.
- Sadick N, et al. (2017). "Belkyra/Kybella: A comprehensive review of the mechanism, clinical efficacy, and safety profile." Journal of Clinical and Aesthetic Dermatology, 10(10), 28-34.
- Mojallal A, et al. (2016). "Submental fat reduction with deoxycholic acid: A systematic review of clinical outcomes and safety." Aesthetic Plastic Surgery, 40(4), 449-458.